Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Pharmacol Res ; 120: 10-22, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28315429

ABSTRACT

Acute kidney injury (AKI) represents a complex clinical condition associated with significant morbidity and mortality. Approximately, 19-33% AKI episodes in hospitalized patients are related to drug-induced nephrotoxicity. Although, considered safe, non-steroidal anti-inflammatory drugs such as diclofenac have received special attention in the past years due to the potential risk of renal damage. Vinpocetine is a nootropic drug known to have anti-inflammatory properties. In this study, we investigated the effect and mechanisms of vinpocetine in a model of diclofenac-induced AKI. We observed that diclofenac increased proteinuria and blood urea, creatinine, and oxidative stress levels 24h after its administration. In renal tissue, diclofenac also increased oxidative stress and induced morphological changes consistent with renal damage. Moreover, diclofenac induced kidney cells apoptosis, up-regulated proinflammatory cytokines, and induced the activation of NF-κB in renal tissue. On the other hand, vinpocetine reduced diclofenac-induced blood urea and creatinine. In the kidneys, vinpocetine inhibited diclofenac-induced oxidative stress, morphological changes, apoptosis, cytokine production, and NF-κB activation. To our knowledge, this is the first study demonstrating that diclofenac-induced AKI increases NF-κB activation, and that vinpocetine reduces the nephrotoxic effects of diclofenac. Therefore, vinpocetine is a promising molecule for the treatment of diclofenac-induced AKI.


Subject(s)
Acute Kidney Injury/chemically induced , Acute Kidney Injury/drug therapy , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Diclofenac/adverse effects , Kidney/drug effects , NF-kappa B/antagonists & inhibitors , Protective Agents/therapeutic use , Vinca Alkaloids/therapeutic use , Acute Kidney Injury/immunology , Acute Kidney Injury/pathology , Animals , Apoptosis/drug effects , Cytokines/immunology , Kidney/immunology , Kidney/pathology , Male , Mice , NF-kappa B/immunology , Nootropic Agents/therapeutic use , Oxidative Stress/drug effects
2.
Neuronal Signal ; 1(3): NS20160010, 2017 Aug.
Article in English | MEDLINE | ID: mdl-32714579

ABSTRACT

Small ubiquitin-like modifier (SUMO) conjugation (or SUMOylation) is a post-translational protein modification implicated in alterations to protein expression, localization and function. Despite a number of nuclear roles for SUMO being well characterized, this process has only started to be explored in relation to membrane proteins, such as ion channels. Calcium ion (Ca2+) signalling is crucial for the normal functioning of cells and is also involved in the pathophysiological mechanisms underlying relevant neurological and cardiovascular diseases. Intracellular Ca2+ levels are tightly regulated; at rest, most Ca2+ is retained in organelles, such as the sarcoplasmic reticulum, or in the extracellular space, whereas depolarization triggers a series of events leading to Ca2+ entry, followed by extrusion and reuptake. The mechanisms that maintain Ca2+ homoeostasis are candidates for modulation at the post-translational level. Here, we review the effects of protein SUMOylation, including Ca2+ channels, their proteome and other proteins associated with Ca2+ signalling, on vital cellular functions, such as neurotransmission within the central nervous system (CNS) and in additional systems, most prominently here, in the cardiac system.

3.
PLoS One ; 11(4): e0153015, 2016.
Article in English | MEDLINE | ID: mdl-27045367

ABSTRACT

In the present study, the effect and mechanism of action of the flavonoid naringenin were evaluated in superoxide anion donor (KO2)-induced inflammatory pain in mice. Naringenin reduced KO2-induced overt-pain like behavior, mechanical hyperalgesia, and thermal hyperalgesia. The analgesic effect of naringenin depended on the activation of the NO-cGMP-PKG-ATP-sensitive potassium channel (KATP) signaling pathway. Naringenin also reduced KO2-induced neutrophil recruitment (myeloperoxidase activity), tissue oxidative stress, and cytokine production. Furthermore, naringenin downregulated KO2-induced mRNA expression of gp91phox, cyclooxygenase (COX)-2, and preproendothelin-1. Besides, naringenin upregulated KO2-reduced nuclear factor (erythroid-derived 2)-like 2 (Nrf2) mRNA expression coupled with enhanced heme oxygenase (HO-1) mRNA expression. In conclusion, the present study demonstrates that the use of naringenin represents a potential therapeutic approach reducing superoxide anion-driven inflammatory pain. The antinociceptive, anti-inflammatory and antioxidant effects are mediated via activation of the NO-cGMP-PKG-KATP channel signaling involving the induction of Nrf2/HO-1 pathway.


Subject(s)
Cytokines/physiology , Flavanones/pharmacology , Inflammation/drug therapy , NF-E2-Related Factor 2/metabolism , Oxidative Stress , Pain/drug therapy , Signal Transduction , Superoxides/metabolism , Animals , Behavior, Animal , Cyclic GMP/metabolism , Cyclic GMP-Dependent Protein Kinases/metabolism , Flavanones/therapeutic use , Inflammation/etiology , Male , Mice , Nitric Oxide/metabolism , Pain/etiology , Potassium Channels/metabolism
4.
Anal Cell Pathol (Amst) ; 2015: 285708, 2015.
Article in English | MEDLINE | ID: mdl-26351625

ABSTRACT

Cancer pain directly affects the patient's quality of life. We have previously demonstrated that the subcutaneous administration of the mammary adenocarcinoma known as Ehrlich tumor induces pain in mice. Several studies have shown that the flavonoid quercetin presents important biological effects, including anti-inflammatory, antioxidant, analgesic, and antitumor activity. Therefore, the analgesic effect and mechanisms of quercetin were evaluated in Ehrlich tumor-induced cancer pain in mice. Intraperitoneal (i.p.) treatments with quercetin reduced Ehrlich tumor-induced mechanical and thermal hyperalgesia, but not paw thickness or histological alterations, indicating an analgesic effect without affecting tumor growth. Regarding the analgesic mechanisms of quercetin, it inhibited the production of hyperalgesic cytokines IL-1ß and TNFα and decreased neutrophil recruitment (myeloperoxidase activity) and oxidative stress. Naloxone (opioid receptor antagonist) inhibited quercetin analgesia without interfering with neutrophil recruitment, cytokine production, and oxidative stress. Importantly, cotreatment with morphine and quercetin at doses that were ineffective as single treatment reduced the nociceptive responses. Concluding, quercetin reduces the Ehrlich tumor-induced cancer pain by reducing the production of hyperalgesic cytokines, neutrophil recruitment, and oxidative stress as well as by activating an opioid-dependent analgesic pathway and potentiation of morphine analgesia. Thus, quercetin treatment seems a suitable therapeutic approach for cancer pain that merits further investigation.


Subject(s)
Carcinoma, Ehrlich Tumor/complications , Pain/drug therapy , Pain/etiology , Quercetin/therapeutic use , Analgesics/pharmacology , Analgesics/therapeutic use , Analgesics, Opioid/pharmacology , Animals , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Behavior, Animal/drug effects , Dose-Response Relationship, Drug , Drug Therapy, Combination , Female , Interleukin-1beta/biosynthesis , Male , Mice , Morphine/pharmacology , Morphine/therapeutic use , Naloxone/pharmacology , Naloxone/therapeutic use , Neutrophil Infiltration/drug effects , Oxidative Stress , Pain/pathology , Quercetin/pharmacology , Skin/pathology , Spinal Cord/pathology , Tumor Necrosis Factor-alpha/biosynthesis
SELECTION OF CITATIONS
SEARCH DETAIL
...